Corlanor

Drug - Corlanor® (ivabradine tablets) [Amgen]

November 2015

Therapeutic area - Heart failure

Approval criteria

The patient or prescribing physician must meet all of the following criteria:

• Patient is 18 years of age or older 
• Patient has a diagnosis of stable, symptomatic heart failure 
• Patient has a left ventricular ejection fraction of ≤ 35% 
• Patient is in normal sinus rhythm with a resting heart rate of ≥ 70 beats per minute 
• Ivabradine will be used in combination with a beta-blocker at maximal dosage or patient has a contraindication to beta-blocker use 
• Patient has tried and failed an ACE inhibitor or ARB 
• Patient has tried and failed a diuretic 
• Patient has tried and failed spironolactone or other aldosterone antagonist

Quantity limit

Maximum of two tablets per day (68 tablets per 34 days)

Background information

Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411